Related Experiment Videos
Neoadjuvant Targeted Molecular Therapy Before Renal Surgery
Sumi Dey1, Henry N Peabody1, Sabrina L Noyes1
1Spectrum Health, 145 Michigan Street NE, Grand Rapids, MI 49503, USA.
Abstract:
Neoadjuvant targeted molecular therapy may benefit select patients with metastatic renal cell carcinoma. The primary use of this therapy in patients with metastatic disease is to reduce tumor burden, prevent distant metastasis, and increase overall survival. Neoadjuvant therapy may reduce tumor size and tumor complexity, facilitate partial nephrectomy rather than radical nephrectomy, downstage tumor thrombus facilitating thrombectomy, and make unresectable tumors resectable when applied to selected patients. These potential benefits of neoadjuvant therapy require further clinical trials to better define the renal function and oncological and survival outcomes in patients receiving each active agent.
Insights
Neoadjuvant targeted molecular therapy shows promise for metastatic renal cell carcinoma patients. This approach may reduce tumor burden, prevent metastasis, and improve survival, potentially enabling less invasive surgeries.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) presents significant treatment challenges.
- Current treatment strategies aim to control disease and improve patient survival.
- Neoadjuvant therapy is increasingly explored to optimize surgical outcomes and systemic control.
Purpose of the Study:
- To evaluate the potential benefits of neoadjuvant targeted molecular therapy in select patients with metastatic renal cell carcinoma.
- To explore how neoadjuvant therapy can reduce tumor burden, prevent metastasis, and enhance overall survival.
- To assess the impact of neoadjuvant therapy on surgical approaches, including partial nephrectomy and thrombectomy.
Main Methods:
- This study focuses on the conceptual framework and potential applications of neoadjuvant therapy.
- It reviews the proposed mechanisms by which targeted molecular agents may impact tumor characteristics.
- The analysis considers outcomes such as tumor size reduction, complexity, and resectability.
Main Results:
- Neoadjuvant therapy may reduce tumor size and complexity, facilitating less radical surgical interventions.
- It has the potential to downstage tumor thrombus, aiding in successful thrombectomy.
- Selected patients may experience improved resectability of initially unresectable tumors.
Conclusions:
- Neoadjuvant targeted molecular therapy offers potential benefits for select metastatic renal cell carcinoma patients.
- Further clinical trials are essential to validate these benefits and define optimal patient selection criteria.
- Investigating renal function, oncological, and survival outcomes is crucial for each active agent.